MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

Enrollment completed in ML-007C-MA's ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004's IRIS Phase 2 trial in autism spectrum disorder Topline results from both Phase 2 trials expected by mid-August 2026 SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc.